Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mainly young women. During the disease course, many organs and systems can suffer non-reversible damage that decreases both the patient’s life span and also their quality of life. To determine the chronic damage and its correlation with quality of life, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index was used in 63 patients who met the ACR criteria for SLE. Quality of life (QOL) was measured through the Medical Outcomes Survey short form 36 (SF-36), sociodemographic data were assessed using specific questionnaires, and disease activity was measured by the systemic lupus erythematosus disease activity index. Overall, 32% of the patients presented damage. Neuropsychiatric (25%) and vascular (20%) involvement were the most frequently related. Organic damages were associated with disease duration (p < 0.03). General health status and social aspects of quality of life were also associated with disease duration (p < 0.05 and p < 0.038, respectively). Socioeconomic status and disease activity were not associated with organic damages and quality of life. This study concluded that disease activity, cumulative damage, and quality of life had some influence in the overall view of lupus but those parameters are distinct domains of health status in SLE. Our analysis identified that disease duration had an important association with damage index and general health status.
Similar content being viewed by others
References
Hochberg MC, Dorsch CA, Feinglass EJ, Stevens MB (1981) Survivorship in systemic lupus erythematosus: effect of antibody to extractable nuclear antigen. Arthritis Rheum 24:54–59
Hochberg MC (1984) Systemic lupus erythematosus VIII. Prognosis. Md State Med J 33:114–116
Hochberg MC (1985) Collagen–vascular disease and disability. In: Hadler NM, Gillings DB (eds) Arthritis and society. Butterworth, London
Ginzler E, Berg A (1987) Mortality in systemic lupus erythematosus. J Rheumatol 14:218–222
Swaak AJ, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, Smeenk RJ (1989) Systemic lupus erythematosus. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48:447–454
Gladman DD (1992) Prognosis of SLE and factors that affect it. Curr Opin Rheumatol 3:789–796
Gladman D, Urowitz M, Fortin P, Isenberg D, Goldsmith C, Gordon C, Petri M (1996) Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol 23:1953–1955
Gladman D, Ginzler E, Goldsmith C, Fortin P, Leang M, Urowitz M, Bacon P, Bombardiere S, Hanly J, Hanly J, Hay E, Isenberg D, Imes J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zomia A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369
Fallowfield L (1992) An overview of quality of life measurements. In: Trimble MR, Dodson WE (eds) Epilepsy and quality of Life. Raven, New York
Testa MA, Simonson DC (1996) Assessment of quality of life outcomes. N Engl J Med 334:835–840
Gladman DD, Urowitz M, Ong A, Gough J, Mackinnon A (1996) A comparison of 5 health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 5:190–195
Stewart AL, Hays RD, Ware JE (1988) The MOS short-form general health survey: reliability and validity in a patient population. Med Care 26:724–735
Fries JF, Spetz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145
Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR (1999) Brazilian–Portuguese version of the SF-36. Reliable and valid quality of life outcome measure. Rev Bras Reumatol 39:143–150
Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, Isenberg DA (1997) Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus and a comparison with the MOS SF-20. J Rheumatol 24:1608–1614
Fortin PR, Abrahamowicz M, Neville C, du Berger R, Fraenkel L, Clarke AE, Danoff D (1998) Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 7:101–107
Tan EM, Cohen AS, Fries JF, Masi AT, McShanie DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythomatosus. Arthritis Rheum 25:1271–1277
Bombardier C, Gladman DD, Urowitz M, Caron D, Chang CH (1992) The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35:630–640
Gladman DD (1994) Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 6:487–492
Rivest C, Lew RA, Welseng PM, Sangha O, Wright EA, Roberts WN, Liang MH, Karlson EW (2000) Association between clinical factors, socio-economic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol 27:680–684
Gladman DD, Urowitz M, Ong A, Gough J, MacKinnon A (1996) Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 14:305–308
Ferraz LB (2001) Avaliação da qualidade de vida em pacientes com Lupus Eritematoso com manifestações cutâneas. UNIFESP, (Tese) São Paulo
Meinão I (2001) Utilização de recursos e custos em pacientes com Lupus Eritematoso Sistêmico. UNIFESP, (Tese) São Paulo
D’Amorim AB (2001) Avaliação das formas auto-administrativas dos questionários MHAQ e SF-12 em pacientes com doenças reumatológicas. UNIFESP, (Tese) São Paulo
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freire, E.A.M., Maia, I.O., Nepomuceno, J.C.A. et al. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheumatol 26, 423–428 (2007). https://doi.org/10.1007/s10067-006-0517-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0517-6